Ciprofloxacin (UTI/Prostatitis)
Brand names: Ciproxin
Ciprofloxacin is an oral and intravenous fluoroquinolone antibiotic; here it is used for complicated UTI and acute or chronic bacterial prostatitis owing to its good prostatic and urinary tissue penetration. Its use is now restricted to situations where other antibiotics are unsuitable.
Adult dose
Paediatric dose
Dose adjustments
Recommended starting and maintenance oral doses in impaired renal function (SPC section 4.2 table): creatinine clearance greater than 60 mL/min/1.73 m² (serum creatinine less than 124 micromol/L) — usual dosage; creatinine clearance 30 to 60 mL/min/1.73 m² (serum creatinine 124 to 168 micromol/L) — 250 to 500 mg every 12 hours; creatinine clearance less than 30 mL/min/1.73 m² (serum creatinine greater than 169 micromol/L) — 250 to 500 mg every 24 hours; patients on haemodialysis — 250 to 500 mg every 24 hours (after dialysis); patients on peritoneal dialysis — 250 to 500 mg every 24 hours. Elderly patients should receive a dose selected according to the severity of the infection and the patient's creatinine clearance.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance, to other quinolones or to any of the excipients
- Concomitant administration of ciprofloxacin and tizanidine
Side effects
- Nausea and diarrhoea — the most commonly reported adverse drug reactions
- Vomiting, gastrointestinal and abdominal pains, dyspepsia (uncommon)
- Headache, dizziness, sleep disorders, taste disorders (uncommon)
- Increase in transaminases, increased bilirubin (uncommon); rash and pruritus (skin section truncated in the fetched text)
- Eosinophilia and mycotic superinfections (uncommon)
- Ventricular arrhythmia, torsades de pointes and ECG QT prolongation (frequency not known; reported predominantly in patients with risk factors for QT prolongation)
Interactions
- Tizanidine — concomitant administration is contraindicated (SPC section 4.3, cross-referencing section 4.5)
- Dairy products (e.g. milk, yoghurt) and mineral-fortified fruit juice (e.g. calcium-fortified orange juice) — ciprofloxacin tablets should not be taken with these (SPC section 4.2 method of administration, cross-referencing section 4.5)
- Note: the section 4.5 interactions text itself was not captured in this source bundle — the full list must be checked against the SPC
Clinical monograph
How it works
It inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and causing bacterial death, with broad Gram-negative activity including many uropathogens.
Prescribing in practice
- Following MHRA warnings, reserve fluoroquinolones for when alternatives cannot be used, and stop at the first sign of tendon pain, neuropathy, or serious psychiatric reactions because some effects can be long-lasting or irreversible.
- It prolongs the QT interval and interacts with multivalent cation antacids, dairy, and other agents that reduce its absorption or compound toxicity.
- Avoid concurrent NSAIDs where possible and use caution in those at risk of aortic aneurysm or seizures per the SPC.
Monitoring
Monitor for tendon, neurological, and psychiatric adverse effects clinically and review blood glucose in those at risk of dysglycaemia.
Counselling the patient
- Stop and seek advice immediately if you develop tendon pain or swelling, pins and needles, or marked mood changes.
- Separate doses from indigestion remedies, dairy, and iron or calcium supplements.
- Avoid excessive sun exposure as the skin may become more sensitive.
Evidence & guidelines
Long-established efficacy in complicated UTI and bacterial prostatitis, with its place in therapy now constrained by regulatory safety reviews.
Reference: MHRA Drug Safety Update 2019; NICE NG112; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- CISNE Score for Febrile Neutropenia · Febrile Neutropenia
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification